This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Discussing the recent FDA approval and potential of Revance’s DAXXIFY, an injection for the treatment of Cervical Dystonia

Ticker(s): RVNC

Who's the expert?

Institution: University of Texas

  • Neurologist, Board certified in neurology, Dr. Mehanna has been in practice since 1995
  • Currently treats 30 patients with cervical dystonia and is 
  • Clinical interest in movement disorders with a focus on Botox injection, deep brain stimulation, intra-operative mapping and post-operative programming.

Interview Questions
Q1.

Roughly how many patients do you treat with cervical dystonia?

Added By: chanell_admin
Q2.

Do you consider switching patients from other toxins to DAXXIFY? Which patient population is suitable for switching? How about new CD patients?

Added By: wzhu0611
Q3.

Does the company provide comprehensive training for the injection? Or it is the same as other toxins?

Added By: wzhu0611

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.